$GILD

Generating a unique summary for GILD…

AI-generated for information only — not investment advice.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

Institutions hold 92.02% · insiders 0.11% · 3,111 institutions

Consensus score 1.68 (1 = strong buy, 5 = sell) · mean target 160.19

• B of A SecuritiesBuymain2026-10-20
• RBC CapitalSector Performmain2026-10-08
• Cantor FitzgeraldOverweightreit2026-10-08
• Truist SecuritiesBuymain2026-10-07
• JP MorganOverweightmain2026-10-07
• Morgan StanleyOverweightmain2026-10-07
• HSBCBuymain2026-09-10
• RBC CapitalSector Performmain2026-08-05
• Cantor FitzgeraldOverweightreit2026-08-05
• NeedhamBuyreit2026-08-05

Next report: 2026-10-29

• N-PXAnnual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PX2026-08-26Open
• 10-QPeriodic Financial Reports2026-08-06Open
• 8-KCorporate Changes & Voting Matters2026-08-04Open
• 8-KCorporate Changes & Voting Matters2026-05-20Open
• 10-QPeriodic Financial Reports2026-05-07Open
• 8-KCorporate Changes & Voting Matters2026-05-04Open
• 8-KCorporate Changes & Voting Matters2026-04-28Open
• SC TO-T/ATender Offer/Acquisition Reports2026-04-17Open
• SC TO-T/ATender Offer/Acquisition Reports2026-04-01Open
• DEF 14AProxy Statements2026-03-20Open

• Gilead Sciences (GILD) Could Be 22% Overvalued Following Its Liver Meeting Update

  Gilead Sciences (GILD) is back in focus after outlining new data it plans to showcase at The Liver Meeting 2026 on its liver disease drugs Livdelzi and Hepcludex, drawing fresh attention to the depth of its pipeline. Recent news has landed against a strong run in Gilead Sciences’ shares, with the 90 day share price return of 20.67% and year to date gain of 28.32% lifting the stock to US$156.04. The 5 year total shareholder return of 187.39% points to sustained momentum rather than a short...

  Sat, 24 Oct 2026 06:10:26 +0000

• Stocktwits Biotech Dealmaker: Gilead And Roche Double Down On Early-Stage Assets Over Full Buyouts This Week

  Inflammation, cancer therapies called antibody-drug conjugates, and next-generation T-cell engagers with possibilities in treating cancer drew the biggest capital in the relatively slow week for biotech dealmaking.

  Sat, 24 Oct 2026 00:01:57 +0000

• The Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement Scheme

  HOUSTON, October 23, 2026--Building on decades of holding pharmaceutical companies responsible for dangerous products and unlawful business practices, The Lanier Law Firm played a pivotal role supporting Texas Attorney General Ken Paxton in securing a $45 million settlement with Gilead Sciences, Inc. Announced on Oct. 22, the settlement resolves claims that the company offered illegal incentives to medical providers to prescribe its drugs over competitors’ medications.

  Fri, 23 Oct 2026 17:27:00 +0000

• Gilead spends $1.28bn on PepStar’s potential Icotyde rival

  Gilead plans to develop HCXT-2001 both as a monotherapy and in combination with its own IBD hopeful, emvistegrast.

  Fri, 23 Oct 2026 12:07:27 +0000

• Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?

  Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on Astute Optics – US’s Substack. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.’s share was trading at $156.51 as of October 20th 2026. GILD’s trailing and forward P/E were 17.84 and 15.55 respectively […]

  Thu, 22 Oct 2026 20:33:22 +0000

• Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD

  FOSTER CITY, Calif., October 22, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held, clinical-stage biotechnology company.

  Thu, 22 Oct 2026 20:05:00 +0000

• Sector Update: Healthcare Stocks Gain Late Afternoon

  Healthcare stocks rose late Thursday afternoon with the NYSE Healthcare Index adding 1.7% and the St

  Thu, 22 Oct 2026 19:56:10 +0000

• Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

  Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  Thu, 22 Oct 2026 13:00:10 +0000